{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-23-070652","form_type":"8-K","ticker":"STOK","cik":"0001623526","company_name":"Stoke Therapeutics, Inc.","filed_at":"2023-03-15T23:59:59+00:00","discovered_at":"2026-05-14T18:03:45.865691+00:00","generated_at":"2026-06-18T02:03:44.500828+00:00","sec_items":["7.01","8.01","9.01"],"event_type":"regulatory","sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"FDA allows Stoke to administer higher 70mg single dose of STK-001 in Dravet syndrome study","bullets":["FDA permits 70mg single dose cohort in Phase 1/2a MONARCH study; dosing expected in coming weeks.","MONARCH remains on partial clinical hold for multiple doses above 45mg; ADMIRAL study continues multiple 70mg dosing.","Data from multiple 45mg doses anticipated mid-2023; data from 70mg (single/multiple) expected H2 2023.","Company on track to complete Phase 1/2a studies in 2023 and initiate Phase 3 program in 2024."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-23-070652","json":"https://secwatch.observer/filing/0001193125-23-070652.json","markdown":"https://secwatch.observer/filing/0001193125-23-070652.md","text":"https://secwatch.observer/filing/0001193125-23-070652.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1623526/000119312523070652/0001193125-23-070652-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1623526/000119312523070652/d452341d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-18T02:03:44.500828+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}